Radiopharmaceuticals: A Guide to Pet/CT and Pet/MRI
暫譯: 放射性藥物：PET/CT與PET/MRI指南
Calabria, Ferdinando, Schillaci, Orazio
- 出版商: Springer
- 出版日期: 2024-08-30
- 售價: $5,880
- 貴賓價: 9.5 折 $5,586
- 語言: 英文
- 頁數: 344
- 裝訂: Hardcover - also called cloth, retail trade, or trade
- ISBN: 3031541952
- ISBN-13: 9783031541957
海外代購書籍(需單獨結帳)
相關主題
商品描述
The book is a practical and concise guide to PET tracers actually useful for PET/CT and PET/MR imaging.
Gaining knowledge on radiopharmaceuticals is often difficult, since their features can be only found in single original journal articles.This book aims to present to the reader, in one single place, clinical features, indications and future trends for PET imaging with a large amount of tracers. While 18F-FDG still remains the miliar stone across PET tracer, new emerging fields of application of PET imaging are consolidated by using disease specific tracers in specific clinical settings.
Each chapter is focused on a single tracer or on a group of similar tracers. The basis and structure of the chapters is the same throughout the book: essential information on synthesis and in vivo distribution of a tracer, clinical cases, eloquently showing clinical indications and usefulness, future trends, scientific literature.
Featuring over 30 radiopharmaceuticals and 240 clinical cases, the 3rd edition has been enriched with additional chapters on the clinical indications and/or common pitfalls for 18F-fluciclovine PET/CT in prostate cancer imaging and for 18F-MISO in PET tumor hypoxia imaging, as well as applications and future directions for 18F-FES and other PET radiopharmaceuticals.
All other chapters of the previous edition have been revised and updated, in particular those chapters covering 18F-DOPA, radiolabeled choline, and 18F-NAF, due to emerging clinical applications for these tracers, 18F-choline for imaging of parathyroid adenoma and 18F-DOPA for restaging of medullary thyroid cancer.
The book will be an invaluable guide for professionals and residents in nuclear medicine, radiology, oncology.
商品描述(中文翻譯)
這本書是一本實用且簡明的指南，介紹對於 PET/CT 和 PET/MR 成像實際有用的 PET 示蹤劑。
獲得放射藥物的知識通常是困難的，因為它們的特徵只能在單一的原始期刊文章中找到。本書旨在將臨床特徵、適應症和 PET 成像的未來趨勢，與大量的示蹤劑集中在一個地方呈現給讀者。雖然 18F-FDG 仍然是 PET 示蹤劑中的里程碑，但透過在特定臨床環境中使用疾病特異性示蹤劑，PET 成像的新興應用領域正在穩固發展。
每一章都專注於單一示蹤劑或一組相似的示蹤劑。各章的基礎和結構在整本書中保持一致：有關示蹤劑的合成和體內分佈的基本信息、臨床案例，清楚地展示臨床適應症和實用性、未來趨勢、科學文獻。
第三版包含超過 30 種放射藥物和 240 個臨床案例，並新增了有關 18F-fluciclovine 在前列腺癌成像中的 PET/CT 臨床適應症和/或常見陷阱，以及 18F-MISO 在 PET 腫瘤缺氧成像中的應用和未來方向的附加章節。
前一版的所有其他章節均已修訂和更新，特別是涵蓋 18F-DOPA、放射性標記膽鹼和 18F-NAF 的章節，因為這些示蹤劑的臨床應用不斷增加，18F-膽鹼用於副甲狀腺腺瘤的成像，18F-DOPA 用於髓樣甲狀腺癌的再分期。
這本書將成為核醫學、放射學和腫瘤學專業人員及住院醫師的寶貴指南。
作者簡介
Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome "Tor Vergata." His specific scientific interest is in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic is the evaluation of the potential added value of hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010, he has been researcher, focusing the attention on prostate cancer imaging with PET/CT and potential applications of PET/MRI in neurology and neuro-oncology, particularly at the Italian National Research Council, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncology and neurology, at the national public Hospital "Mariano Santo" in Cosenza, Italy. The author of over 50 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine and radiology.
Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome "La Sapienza." He began his scientific work at the University of L'Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome "Tor Vergata" in 2001. Since 2008 he has led the School of Specialization in Nuclear Medicine and, since 2013, has been Director of the School Of Medicine at the "Tor Vergata" University Hospital in Rome. The author of more than 220 scientific articles listed in PubMed, his current research interest is in the development of novel PET radiopharmaceuticals and their potential clinical applications in oncology, neurology, cardiology and infectious disease, within a network involving several Italian and European institutions. He is also the former President of the Italian Association of Nuclear Medicine.
作者簡介(中文翻譯)
費爾迪南多·卡拉布里亞博士於2005年獲得醫學學位，並於2009年在羅馬「托爾維爾加大學」專攻核醫學。他的具體科學興趣在於深入了解正電子發射斷層掃描（PET）放射性藥物的生物分佈的生理病理特徵，以驗證進一步的診斷應用。另一個主題是評估使用SPECT/CT和PET/CT掃描儀的混合影像的潛在附加價值。自2010年以來，他一直擔任研究員，專注於前列腺癌的PET/CT影像學以及PET/MRI在神經學和神經腫瘤學中的潛在應用，特別是在意大利國家研究委員會，採用多學科網絡方法。他目前正在探索在意大利科森扎的國立公立醫院「馬里亞諾·聖托」中，使用SPECT/CT和PET/CT的先進混合影像在腫瘤學和神經學中的角色。作為PubMed上列出的50多篇科學論文的作者，他還擔任核醫學和放射學主要專業科學期刊的審稿人。
奧拉齊奧·希拉奇教授於1990年獲得醫學學位，並於1994年在羅馬「拉薩比恩扎大學」專攻核醫學。他在拉奎拉大學開始了他的科學工作：在這一重要時期，希拉奇開始探索分子影像學，重點研究神經內分泌腫瘤的SPECT。經過在美國加州的研究逗留後，他於2001年成為羅馬「托爾維爾加大學」的核醫學教授。自2008年以來，他一直領導核醫學專科學校，自2013年以來，擔任羅馬「托爾維爾加大學醫院」醫學院的院長。他是PubMed上列出的220多篇科學文章的作者，目前的研究興趣在於開發新型PET放射性藥物及其在腫瘤學、神經學、心臟病學和傳染病中的潛在臨床應用，並涉及多個意大利和歐洲機構的網絡。他也是意大利核醫學協會的前任會長。
